Orlistat Sandoz

Orlistat, the active ingredient in Orlistat Sandoz, is a lipase inhibitor presented as a tablet for oral use. It reduces dietary fat absorption and is used in the management of obesity and overweight in adults. GNH USA supplies Orlistat Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orlistat is indicated for the treatment of obesity and overweight conditions, acting on the gastrointestinal absorption of dietary fat.

- Obesity: assists in weight loss when combined with a reduced‑calorie, low‑fat diet. - Overweight: supports modest weight reduction in adults with a BMI of 27–30 kg/m² who have weight‑related risk factors. - Weight management: used as part of a comprehensive lifestyle program that includes diet, exercise and behavioral changes.

Orlistat may cause gastrointestinal and nutritional adverse reactions.

Common Side Effects: - Oily spotting: oily discharge on underwear after bowel movements. - Flatulence with discharge: increased gas accompanied by oily stool. - Fecal urgency: sudden need to defecate. - Abdominal cramps: intermittent stomach pain. - Increased defecation frequency: more frequent bowel movements. - Fatty/oily stool: pale, oily stools.

Serious or Rare Side Effects: - Liver injury: rare cases of hepatitis or hepatic dysfunction. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Fat‑soluble vitamin deficiency: reduced absorption of vitamins A, D, E, K. - Pancreatitis: inflammation of the pancreas. - Intestinal obstruction: blockage of the bowel.

Before initiating therapy, several safety considerations should be addressed.

- Assess BMI: confirm patient meets BMI criteria for obesity or overweight treatment. - Dietary fat intake: advise a low‑fat diet (≤30 g per meal) to minimize gastrointestinal side effects. - Vitamin supplementation: recommend a multivitamin containing vitamins A, D, E and K taken at least 2 hours apart from the drug. - Pregnancy and lactation: avoid use unless the potential benefit justifies the potential risk to the fetus or infant. - Drug interactions: review concomitant medications such as cyclosporine, warfarin and levothyroxine for possible interaction. - Store at room temperature: keep in the original container, protect from moisture and heat.

Orlistat can affect the absorption of several drugs and nutrients.

Major Interactions (Avoid): - Cyclosporine: reduced absorption may lower immunosuppressive efficacy. - Warfarin: increased INR; monitor coagulation parameters closely. - Levothyroxine: decreased absorption; separate dosing by at least 4 hours.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: enhanced glycemic control may increase hypoglycemia risk. - Fat‑soluble vitamins: decreased absorption; supplement as needed. - Oral contraceptives: potential reduction in hormone levels; consider alternative contraception.